BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 24360887)

  • 1. Pilot study of angiogenic response to yttrium-90 radioembolization with resin microspheres.
    Carpizo DR; Gensure RH; Yu X; Gendel VM; Greene SJ; Moore DF; Jabbour SK; Nosher JL
    J Vasc Interv Radiol; 2014 Feb; 25(2):297-306.e1. PubMed ID: 24360887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib.
    Lewandowski RJ; Andreoli JM; Hickey R; Kallini JR; Gabr A; Baker T; Kircher S; Salem R; Kulik L
    J Vasc Interv Radiol; 2016 Sep; 27(9):1329-1336. PubMed ID: 27266362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
    Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E
    J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.
    Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B
    J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Same-Day Yttrium-90 Radioembolization: Feasibility with Resin Microspheres.
    Li MD; Chu KF; DePietro A; Wu V; Wehrenberg-Klee E; Zurkiya O; Liu RW; Ganguli S
    J Vasc Interv Radiol; 2019 Mar; 30(3):314-319. PubMed ID: 30819470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.
    Miyahara K; Nouso K; Tomoda T; Kobayashi S; Hagihara H; Kuwaki K; Toshimori J; Onishi H; Ikeda F; Miyake Y; Nakamura S; Shiraha H; Takaki A; Yamamoto K
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1604-11. PubMed ID: 22011296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization.
    Abuodeh Y; Naghavi AO; Ahmed KA; Venkat PS; Kim Y; Kis B; Choi J; Biebel B; Sweeney J; Anaya DA; Kim R; Malafa M; Frakes JM; Hoffe SE; El-Haddad G
    World J Gastroenterol; 2016 Dec; 22(47):10406-10414. PubMed ID: 28058021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Radioembolization in the Setting of Angiographically Apparent Arterioportal Shunting.
    Thornton LM; Geller BS; Pepin EW; Shah JL; Kapp M; Toskich BB
    J Vasc Interv Radiol; 2018 Nov; 29(11):1511-1518. PubMed ID: 30293727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Patients with Unresectable Hepatocellular Carcinoma Treated with Radioembolization.
    Sukato DC; Tohme S; Chalhoub D; Han K; Zajko A; Amesur N; Orons P; Marsh JW; Geller DA; Tsung A
    J Vasc Interv Radiol; 2015 Jun; 26(6):816-24.e1. PubMed ID: 25824315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine and Chemokine Concentration in the Tear of Patients with Age-Related Cataract.
    Engelbrecht C; Sardinha LR; Rizzo LV
    Curr Eye Res; 2020 Sep; 45(9):1101-1106. PubMed ID: 31928443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioembolization with infusion of yttrium-90 microspheres into a right inferior phrenic artery with hepatic tumor supply is feasible and safe.
    Burgmans MC; Kao YH; Irani FG; Dames EL; Teo TK; Goh AS; Chow PK; Tay KH; Lo RH
    J Vasc Interv Radiol; 2012 Oct; 23(10):1294-301. PubMed ID: 22922039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological changes in nontumoral liver secondary to radioembolization of hepatocellular carcinoma with yttrium 90-impregnated microspheres: report of two cases.
    Dhingra S; Schwartz M; Kim E; Mabel Ko H; Ward SC; Fiel MI; Thung SN
    Semin Liver Dis; 2014 Nov; 34(4):465-8. PubMed ID: 25369308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of Survival after Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases.
    Weiner AA; Gui B; Newman NB; Nosher JL; Yousseff F; Lu SE; Foltz GM; Carpizo D; Lowenthal J; Zuckerman DA; Benson B; Olsen JR; Jabbour SK; Parikh PJ
    J Vasc Interv Radiol; 2018 Aug; 29(8):1094-1100. PubMed ID: 29754852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Dosimetry and Outcomes of Hepatocellular Carcinoma Treated by Yttrium-90 Resin Microsphere Radioembolization: A Retrospective Analysis Using Technetium-99m Macroaggregated Albumin SPECT/CT and Planning Software.
    Doyle PW; Workman CS; Grice JV; McGonigle TW; Huang S; Borgmann AJ; Baker JC; Duncan DP; Taylor JE; Brown DB
    J Vasc Interv Radiol; 2024 May; 35(5):689-698.e3. PubMed ID: 38246416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Yttrium-90 Radioembolization for Unresectable Combined Biphenotypic Hepatocellular-Cholangiocarcinoma.
    Malone CD; Gibby W; Tsai R; Kim SK; Lancia S; Akinwande O; Ramaswamy RS
    J Vasc Interv Radiol; 2020 May; 31(5):701-709. PubMed ID: 32127318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis.
    Tsai AL; Burke CT; Kennedy AS; Moore DT; Mauro MA; Dixon RD; Stavas JM; Bernard SA; Khandani AH; O'Neil BH
    J Vasc Interv Radiol; 2010 Sep; 21(9):1377-84. PubMed ID: 20691606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma.
    Sangro B; Bilbao JI; Boan J; Martinez-Cuesta A; Benito A; Rodriguez J; Panizo A; Gil B; Inarrairaegui M; Herrero I; Quiroga J; Prieto J
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):792-800. PubMed ID: 16904840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
    Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
    J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yttrium-90 Radioembolization with Resin Microspheres without Routine Embolization of the Gastroduodenal Artery.
    Ward TJ; Louie JD; Sze DY
    J Vasc Interv Radiol; 2017 Feb; 28(2):246-253. PubMed ID: 27884683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.